Evolution of biomarkers of liver fibrosis and liver insufficiency in hepatitis C virus-infected patients treated with pegylated interferon plus ribavirin and rituximab

Journal of Viral Hepatitis, 06/12/2012

No beneficial effects of RTX were evidenced on liver fibrosis progression, but authors found interesting correlations with the serum albumin level, FibroTest values and B–cell count.

Print Article Summary